TLR7
Toll-like receptor 7
As of the edition of 20 October 2026, TLR7 (toll-like receptor 7, UniProt Q9NYK1) has 19 drugs tested at it and 27 companies on the list, 8 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NYK1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Cancer; Infections; Lungs and airways; Skin and connective tissue; Immune system; Urinary and reproductive; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 603
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 5 |
| Went quiet | 4 |
| Stopped | 6 |
| Status not established | 2 |
| Total | 19 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Hydroxychloroquine | Marketed | Phase 4 | none listed |
| Imiquimod | Marketed | Phase 4 | none listed |
| Resiquimod | Stopped | Phase 2 | none listed |
| Enpatoran | Active | Phase 3 | none listed |
| Afimetoran | Active | Phase 2 | none listed |
| AZD-8848 | Went quiet | Phase 2 | none listed |
| Vesatolimod | Stopped | Phase 2 | none listed |
| CPG-52852 | Stopped | Phase 2 | none listed |
| GSK-2245035 | Stopped | Phase 2 | none listed |
| Bazlitoran | Went quiet | Phase 2 | none listed |
| EIK1001 | Active | Phase 3 | none listed |
| Ruzotolimod | Active | Phase 2 | none listed |
12 of 19 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 2 |
| Engaged | 11 |
| Undetermined | 6 |
| Total on the list | 27 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| AstraZeneca | Route A |
| Gilead Sciences | Route A |
The other 24 companies at TLR7
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at TLR7, ranked, with the facts behind eachRequest access. Nothing is shown until you do.